EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Multizentrische Studie

Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

Enriqueta Felip, Giulio Metro, Ross A Soo, Jürgen Wolf, Benjamin J Solomon, Daniel Sw Tan, Andrea Ardizzoni, Dae Ho Lee, Lecia V Sequist, Fabrice Barlesi, Santiago Ponce-Aix, Delvys Rodriguez Abreu und 11 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114182 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Enriqueta Felip und 22 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. Electronic address: efelip@…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Novartis AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsMutationTriazinesHumansMaleFemaleMiddle AgedAgedAdultBenzamidesAged, 80 and overProtein Kinase InhibitorsImidazoles

Stichwörter der Autor:innen

CapmatinibEGFRMETNSCLCNazartinib

Substanzen

ErbB ReceptorsEGFR protein, humanTriazinescapmatinibBenzamidesProtein Kinase InhibitorsImidazoles

Autor:innen und Institutionen

  • Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain. Electronic address: efelip@vhio.net.
  • Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy.
  • National University Cancer Institute Singapore, Singapore.
  • Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
  • Peter MacCallum Cancer Centre, Melbourne, Australia.
  • National Cancer Centre, Duke-NUS Medical School, Singapore.

Förderung

  • Novartis AG

Zitieren

APA

Felip, E., Metro, G., Soo, R. A., Wolf, J., Solomon, B. J., Tan, D. S., Ardizzoni, A., Lee, D. H., Sequist, L. V., Barlesi, F., Ponce-Aix, S., Abreu, D. R., Campelo, M. R. G., Sprauten, M., Djentuh, L. O., Smith, N., Jary, A., Belli, R., Glaser, S., …, & Yang, J. C. (2024). Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114182

Vancouver

Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, et al. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114182

BibTeX
@article{Felip2024,
  author = {Felip, Enriqueta and Metro, Giulio and Soo, Ross A and Wolf, Jürgen and Solomon, Benjamin J and Tan, Daniel Sw and Ardizzoni, Andrea and Lee, Dae Ho and Sequist, Lecia V and Barlesi, Fabrice and Ponce-Aix, Santiago and Abreu, Delvys Rodriguez and Campelo, Maria Rosario Garcia and Sprauten, Mette and Djentuh, Leslie O'Sullivan and Smith, Nathalie and Jary, Aline and Belli, Riccardo and Glaser, Sabine and Zou, Mike and Cui, Xiaoming and Giovannini, Monica and Yang, James Chih-Hsin},
  title = {Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114182}
}
Kostenlos starten →